idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Thema Corona

Imagefilm
Science Video Project
idw-News App:

AppStore



Teilen: 
17.05.2021 21:00

New Technology Makes Tumor Eliminate Itself

Rita Ziegler Kommunikation
Universität Zürich

    A new technology developed by UZH researchers enables the body to produce therapeutic agents on demand at the exact location where they are needed. The innovation could re-duce the side effects of cancer therapy and may hold the solution to better delivery of Covid-related therapies directly to the lungs.

    Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells. Once inside tumor cells, the delivered genes serve as a blueprint for therapeutic antibodies, cytokines and other signaling substances, which are produced by the cancer cells themselves and act to elimi-nate tumors from the inside out.

    Sneaking adenoviruses past the immune system undetected

    “We trick the tumor into eliminating itself through the production of anti-cancer agents by its own cells,” says postdoctoral fellow Sheena Smith, who led the development of the delivery approach. Research group leader Andreas Plückthun explains: “The therapeutic agents, such as therapeu-tic antibodies or signaling substances, mostly stay at the place in the body where they’re needed instead of spreading throughout the bloodstream where they can damage healthy organs and tissues.”

    The UZH researchers call their technology SHREAD: for SHielded, REtargetted ADenovirus. It builds on key technologies previously engineered by the Plückthun team, including to direct ade-noviruses to specified parts of the body to hide them from the immune system.

    High amount of drugs in the tumor, low concentration in other tissues

    With the SHREAD system, the scientists made the tumor itself produce a clinically approved breast cancer antibody, called trastuzumab (Herceptin®), in the mammary of a mouse. They found that, after a few days, SHREAD produced more of the antibody in the tumor than when the drug was injected directly. Moreover, the concentration in the bloodstream and in other tissues where side effects could occur were significantly lower with SHREAD. The scientists used a very sophisticated, high-resolution 3D imaging method and tissues rendered totally transparent to show how the therapeutic antibody, produced in the body, creates pores in blood vessels of the tumor and destroys tumor cells, and thus treats it from the inside.

    Use to combat Covid-19 being investigated

    Plückthun, Smith and colleagues emphasize that SHREAD is applicable not only for the fight against breast cancer. As healthy tissues no longer come into contact with significant levels of the therapeutic agent, it is also applicable for delivery of a wide range of so-called biologics – power-ful protein-based drugs that would otherwise be too toxic.

    In fact, members of the Plückthun group are currently applying their technology in an SNF-funded project aimed as a therapy for Covid-19. Adenoviral vectors are already being used in several of the COVID vaccines, including the Johnson & Johnson, AstraZeneca, China’s CanSino Biologics and Russia’s Sputnik V vaccines – but without the innovative SHREAD technology. “By delivering the SHREAD treatment to patients via an inhaled aerosol, our approach could allow targeted production of Covid antibody therapies in lung cells, where they are needed most,” Smith ex-plains. “This would reduce costs, increase accessibility of Covid therapies and also improve vac-cine delivery with the inhalation approach.”

    -------------------

    Funding:
    This work was supported by Swiss National Science Foundation (Sinergia Grant 170929) and National Cancer Institute of the NIH (F32CA189372).
    The ongoing COVID project is supported by Swiss National Science Foundation (NRP78, 198287).


    Wissenschaftliche Ansprechpartner:

    Prof. Dr. Andreas Plückthun
    Biochemisches Institut
    Universität Zürich
    Telefon: +41 44 635 55 70
    plueckthun@bioc.uzh.ch


    Originalpublikation:

    Smith, S. N., Schubert, R., Brücher, D., Simic, B., Schmid, M., Kirk, N., Freitag, P., Gradinaru, V. and Plückthun, A.The SHREAD gene therapy platform for paracrine delivery improves tumor local-ization and intratumoral effects of a clinical antibody as shown by PACT. PNAS. 17 May 2021. DOI: 10.1073/pnas.2017925118


    Merkmale dieser Pressemitteilung:
    Journalisten
    Biologie, Chemie, Ernährung / Gesundheit / Pflege, Medizin
    überregional
    Forschungsergebnisse, Forschungsprojekte
    Englisch


    Inside the tumor: A piece of the tumor was made transparent and scanned in 3D. The components labeled with fluorescent colors were rendered in a 3D representation on the computer (red: blood vessels, turquoise: tumor cells, yellow: therapeutic antibody).


    Zum Download

    x

    Hilfe

    Die Suche / Erweiterte Suche im idw-Archiv
    Verknüpfungen

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.

    Klammern

    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).

    Wortgruppen

    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.

    Auswahlkriterien

    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).